ORGS vs. CEMI, ANVS, BTAI, VHAQ, RLYB, BLRX, MNOV, ELDN, AFMD, and CALC
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Chembio Diagnostics (CEMI), Annovis Bio (ANVS), BioXcel Therapeutics (BTAI), Viveon Health Acquisition (VHAQ), Rallybio (RLYB), BioLineRx (BLRX), MediciNova (MNOV), Eledon Pharmaceuticals (ELDN), Affimed (AFMD), and CalciMedica (CALC). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Chembio Diagnostics (NASDAQ:CEMI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Chembio Diagnostics has higher revenue and earnings than Orgenesis.
In the previous week, Orgenesis had 2 more articles in the media than Chembio Diagnostics. MarketBeat recorded 2 mentions for Orgenesis and 0 mentions for Chembio Diagnostics. Orgenesis' average media sentiment score of 1.74 beat Chembio Diagnostics' score of 0.00 indicating that Orgenesis is being referred to more favorably in the media.
Orgenesis has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Chembio Diagnostics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 8.6% of Chembio Diagnostics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 3.3% of Chembio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Chembio Diagnostics received 272 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 53.22% of users gave Chembio Diagnostics an outperform vote.
Chembio Diagnostics has a net margin of -47.03% compared to Orgenesis' net margin of -1,343.97%. Chembio Diagnostics' return on equity of -113.57% beat Orgenesis' return on equity.
Summary
Chembio Diagnostics beats Orgenesis on 7 of the 13 factors compared between the two stocks.
Get Orgenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orgenesis Competitors List
Related Companies and Tools
